Prot #AMV564-101: A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Project: Research project

Project Details

StatusFinished
Effective start/end date10/18/18 → 10/18/21

Funding

  • Amphivena Therapeutics, Inc. (Prot #AMV564-101)